quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:01:00·49d
PRRelease
Erasca Inc. logo
Tango Therapeutics Inc. logo

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

ERAS· Erasca Inc.TNGX· Tango Therapeutics Inc.
Health Care
Original source

Companies

  • ERAS
    Erasca Inc.
    Health Care
  • TNGX
    Tango Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 3TNGXUpdateCanaccord Genuity$30.00
  • Apr 2TNGXUpdateCanaccord Genuity$30.00
  • Feb 23TNGXUpdateMizuho$19.00
  • Jan 27ERASUpdateMizuho$16.00
  • Jan 7ERASUpdatePiper Sandler$5.00
  • Nov 18TNGXUpdateWolfe Research-

Related

  • SEC2d
    Erasca Inc. filed SEC Form 8-K: Other Events
  • SEC6d
    SEC Form DEFA14A filed by Tango Therapeutics Inc.
  • SEC6d
    SEC Form DEF 14A filed by Tango Therapeutics Inc.
  • INSIDER7d
    SEC Form 4 filed by Crystal Adam
  • SEC8d
    Tango Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR8d
    Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
  • ANALYST20d
    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target
  • INSIDER20d
    SEC Form 4 filed by Garner Ebun
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022